ADReCS

Pharmaceutical Information

Drug Name	Apomorphine
Drug ID	BADD_D00152
Description	Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.[A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919]
Indications and Usage	Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.[L13919,L13922]
Marketing Status	approved; investigational
ATC Code	G04BE07; N04BC07
DrugBank ID	DB00714
KEGG ID	D07460
MeSH ID	D001058
PubChem ID	6005
TTD Drug ID	D0H6QU
NDC Product Code	Not Available
UNII	N21FAR7B4S
Synonyms	Apomorphine \| Apomorphine Hydrochloride, Anhydrous \| Apomorphine Hydrochloride Anhydrous \| Apomorphine Hydrochloride \| Apomorphin-Teclapharm \| Apomorphin Teclapharm \| Apomorphine Hydrochloride, Hemihydrate \| Apokinon \| Apomorphine Chloride \| Britaject

Chemical Information

Molecular Formula	C17H17NO2
CAS Registry Number	58-00-4
SMILES	CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Injection site inflammation	12.07.03.009; 08.02.03.008	0.000273%		Not Available
Injection site necrosis	12.07.03.020; 08.02.03.020	0.000546%		Not Available
Injection site pain	12.07.03.011; 08.02.03.010	0.000927%		Not Available
Injection site pruritus	23.03.12.007; 12.07.03.014; 08.02.03.013	0.002164%		Not Available
Injection site rash	23.03.13.010; 12.07.03.032; 08.02.03.032	0.000618%		Not Available
Injection site reaction	08.02.03.014; 12.07.03.015	0.000618%
Insomnia	19.02.01.002; 17.15.03.002	0.001018%
Intestinal obstruction	07.13.01.002	0.000455%		Not Available
Jaundice	23.03.03.030; 09.01.01.004; 01.06.04.004	0.000273%		Not Available
Libido increased	19.08.03.002; 21.03.02.007	-	-
Loss of consciousness	17.02.04.004	0.001109%		Not Available
Malaise	08.01.01.003	0.001418%
Mania	19.16.02.002	0.000582%
Mood altered	19.04.02.007	0.000400%		Not Available
Muscle rigidity	17.05.02.005; 15.05.04.001	0.000182%		Not Available
Myocardial infarction	24.04.04.009; 02.02.02.007	0.000273%
Nasopharyngitis	22.07.03.002; 11.01.13.002	-	-	Not Available
Nausea	07.01.07.001	0.008183%
Oedema	14.05.06.010; 08.01.07.006	-	-	Not Available
Oedema peripheral	02.05.04.007; 14.05.06.011; 08.01.07.007	0.000400%
On and off phenomenon	17.01.05.004	0.004019%		Not Available
Orthostatic hypotension	24.06.03.004; 17.05.01.020	-	-	Not Available
Pain in extremity	15.03.04.010	0.000800%
Pallor	23.03.03.031; 08.01.03.032; 24.03.04.001	-	-	Not Available
Palpitations	02.11.04.012	0.000400%
Panic attack	19.06.04.001	0.000400%		Not Available
Panniculitis	23.07.02.002; 10.01.03.024	0.000636%		Not Available
Paranoia	19.05.01.005	0.000618%		Not Available
Pneumonia	22.07.01.003; 11.01.09.003	-	-	Not Available
Priapism	24.04.12.007; 21.03.01.005	-	-	Not Available

The 3th Page First Pre 3 4 5 Next Last Total 5 Pages